Skip to main content
. 2022 Oct 5;13:988836. doi: 10.3389/fphar.2022.988836

TABLE 4.

Summary of subgroup analysis on brain water content.

Pooled estimates No. of studies Std. MD (95% CI) p value Group p-value
Model <0.00001
MCAO 8 −5.51 [−6.21, −4.80] p < 0.00001
BCCAO 1 −16.41 [−17.67, −15.15] p < 0.00001
Species
 SD rats 9 −8.10 [−8.71, −7.48] p < 0.00001
 Route of administration <0.00001
i.p 7 −7.84 [−8.49, −7.20] p < 0.00001
i.v 1 −17.46 [−21.30, −13.62] p < 0.00001
ICA 1 −7.98 [−10.50, −5.46] p < 0.00001
 Dosage <0.00001
 <20 mg/kg 3 −4.90 [−6.08, −3.71] p < 0.00001
 20 mg/kg 2 −9.83 [−10.70, −8.97] p < 0.00001
 30 mg/kg 2 −4.38 [−5.80, −2.96] p < 0.00001
 >30 mg/kg 3 −7.22 [−8.64, −5.81] p < 0.00001
 Administration time <0.00001
 Before I/R 3 −10.09 [−10.95, −9.22] p < 0.00001
 After I/R 5 −8.49 [−9.80, −7.19] p < 0.00001
 Before and after I/R 1 −4.04 [−5.22, −2.86] p < 0.00001
 Occlusion time <0.00001
 60 min 1 −5.34 [−7.36, −3.33] p < 0.00001
 90 min 2 −5.21 [−6.34, −4.08] p < 0.00001
 120 min 6 −9.92 [−10.71, −9.13] p < 0.00001

BCCAO, the bilateral common carotid arteries occlusion; MCAO, middle cerebral artery occlusion; ICA, intra-carotid artery; I/R, ischemia/reperfusion; i.g., intragastric gavage; i.p., intraperitoneal; i.v., intravenous injection; SD, Sprague-Dawley.